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Abstract
Although breast cancer incidence continues to 
increase, mortality has been decreasing, principally as 
a result of earlier detection and improvements in adju-
vant systemic therapy. Nonetheless, because antineo-
plastic agents are associated with substantial morbid-
ity and occasional mortality, efforts to individualize 
treatment strategies are desirable. In addition to clas-
sic histopathologic diagnosis, molecular and cellular 
tumor markers may help in establishing prognosis or 
prediction of benefit. 
 Recommendations for routine use of tumor mark-
ers in breast cancer have been conservative. Although 
several studies have been reported, few are of suffi-
ciently high level of evidence to permit solid conclu-
sions. Three key issues in tumor marker evaluation are 
utility, magnitude, and reliability. Poorly conceived 
study designs cloud the issue of how the marker might 
be used. Reliance on p-values rather than the size of the 
differences in outcome between patients who are posi-
tive and those who are negative for the factor obscures 
the importance. Technical issues result in poor repro-
ducibility and interpretability of assays. Analytical 
issues lead to poorly defined cutoff values for marker 
levels. Poor patient selection leads to difficulty inter-
preting results because of confounders such as differ-
ences in treatment regimens. This review focuses on 
these issues, with an emphasis on currently accepted 
tumor markers. Finally, new tumor marker report-
ing recommendations are discussed, the adoption of 
which may lead to improved design and publication 
of tumor marker studies in the future. The Oncologist 
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Introduction
Breast cancer is the most common cancer in women in the 
U.S., with an estimated 213,000 new cases diagnosed in the 
U.S. in 2005 [1]. Despite these increasing numbers, mortal-
ity from breast cancer continues to decline. This decline 
is felt to be a result of a combination of earlier detection of 
disease as a result of screening and improved treatment of 
disease with adjuvant systemic therapies [2, 3]. A major-
ity of patients are cured with surgery and radiation therapy 
alone, and these patients will gain no additional benefit 
from adjuvant systemic therapies. In addition, having a high 
risk for recurrence does not imply that systemic therapy will 
prevent it. Even for those who recur, overall survival and 
palliation of symptoms for patients with metastatic breast 
cancer (MBC) has improved with the advent of new thera-
pies. However, currently available methods are inadequate 
to help the clinician precisely predict a priori which patients 
will benefit from many of the available therapies.
For patients with early-stage breast cancer, it would be 
helpful to identify which patients will relapse without adju-
vant systemic therapy, so that only patients who receive ben-
efit are exposed to the inherent toxicities. Approach to treat-
ment of metastatic disease is generally with palliative intent 
rather than for cure. In this setting, identification of those 
patients with rapidly progressive disease permits selection 
of more rapidly acting but perhaps more toxic therapy. 
During the past few decades, with the explosion of 
molecular technology and understanding of the biology of 
breast cancer, numerous studies have been performed to 
identify prognostic and predictive factors in breast cancer, 
with mixed success. Multiple expert panels have convened 
to analyze available data in order to establish guidelines for 
the use of tumor markers, but their recommendations have 
been very conservative [4, 5]. In this review, we address 
the pitfalls that have led to difficulties establishing tumor 
markers for routine clinical use, with a specific focus on 
tumor markers in breast cancer.
American Society of Clinical 
Oncology Guidelines 
The American Society of Clinical Oncology (ASCO) 
convened a panel of experts that first published recom-
mendations regarding the use of circulating and tissue-
based tumor markers in breast cancer in 1996 [6] and most 
recently updated these recommendations in 2001(Table 1) 
[4]. The ASCO panel evaluated multiple serum markers for 
breast cancer, including assays for MUC1 protein (cancer 
antigen [CA] 15-3 and CA 27.29), carcinoembryonic anti-
gen (CEA), and the circulating extracellular domain of Her-
2/neu. The panel did not recommend monitoring of any of 
these markers for screening, diagnosis, staging, or routine 
surveillance of patients free of detectable disease. Mea-
surement of CA 15-3 or CA 27.29 and/or CEA was recom-
mended, however, to monitor selected patients with MBC 
undergoing palliative therapy [7]. 
Routine measurement of multiple tissue markers was also 
discussed in the guidelines. The panel recommended routine 
measurement of estrogen and progesterone receptors (ER 
and PgR, respectively) to identify patients most likely to ben-
efit from endocrine therapy in either the early or metastatic 
disease settings. In addition, measurement of Her-2/neu over-
expression and possibly amplification was recommended for 
all patients at the time of initial diagnosis or recurrence, as it 
is predictive of response to trastuzumab (Herceptin®; Genen-
tech, South San Francisco, CA), a monoclonal antibody 
directed against the Her-2/neu receptor [8–10]. The panel felt 
that data to support assessment of other tissue-based mark-
ers, including p53, cathepsin D, and flow cytometry-derived 
estimates of DNA content or S phase, were insufficient to 
recommend usage in routine clinical practice.
Therefore, despite the large number of research studies 
evaluating the prognostic and predictive ability of numer-
ous tumor markers in breast cancer, the ASCO panel rec-
ommended few for routine use in clinical practice. Why 
were these recommendations so conservative? In the suc-
ceeding sections of this paper, we outline the multiple fac-
tors that underlie this conservative approach.
When Is a Tumor Marker Useful (Use)?
When evaluating tumor markers for use in clinical practice, 
clinicians should consider their utility, the magnitude of 
their effects, and their reliability (Table 2). Tumor mark-
ers can be useful at multiple stages of cancer diagnosis and 
treatment (Table 3) [11, 12]. For example, for individuals 
who do not have cancer, a marker may be helpful in deter-
mining the risk for developing the disease and/or it may be 
beneficial for screening for disease. Once an abnormality 
is found, a tumor marker may be helpful for distinguishing 
between benign and malignant processes or between dif-
ferent malignant processes. After confirmation of a cancer 
diagnosis, tumor markers can help monitor disease status 
during and after therapy.
Tumor markers can also help determine prognosis inde-
pendent of therapy and predict response to therapy. Prognos-
tic factors reflect the metastatic potential and/or growth rate 
of the tumor and are used to select patient outcomes without 
consideration of treatment given [13]. Predictive factors, on 
the other hand, reflect the sensitivity or resistance of a tumor 
to a therapeutic agent and therefore are used to predict which 
patients are likely to respond to a specific treatment [14]. 
Pure prognostic and predictive factors are depicted sche-
matically in Figures 1A and 1B, respectively.
Henry, Hayes    543
www.TheOncologist.com
Few tumor markers are purely prognostic or predictive. 
In fact, most tumor markers have mixed prognostic and 
predictive features, and the utility typically depends on the 
therapeutic agent in question. For example, ER expression 
is weakly favorably prognostic but strongly predictive of 
response to treatment with endocrine therapy, as illustrated 
in Figure 1C. Her-2/neu overexpression, on the other hand, 
is an unfavorable prognostic factor and is strongly predic-
tive of response to therapy with trastuzumab, as shown in 
Figure 1D. Until appropriate studies have been performed 
both in vitro and in vivo, it can be difficult to know how to 
use a tumor marker appropriately in the clinical setting. In 
breast cancer, tumor markers are currently used in only a 
few of these categories.
How Useful Is the Tumor Marker 
(Magnitude)?
Once a tumor marker use has been identified, it is impor-
tant to determine the magnitude of the difference in out-
comes for that particular use between those who are marker 
positive and those who are not. By evaluating the difference 
in outcome, regardless of treatment, between a patient posi-
tive for a given prognostic factor and one who is negative for 
the factor, the relative strength of a prognostic factor can be 
determined [15]. This assessment requires the selection of 
an appropriate outcome of interest, such as improvement 
in symptoms or survival, or surrogates of these end points, 
such as response rates or progression-free survival. 
For example, a breast cancer patient with disease in the 
lymph nodes at the time of diagnosis is two to three times 
more likely to have a breast cancer event (local recurrence 
or distant metastasis) than a patient without lymph node 
involvement, regardless of treatment. Since lymph node 
status has classically been used to make clinical decisions, 
Table 1. Summary of American Society of Clinical Oncology guidelines for use of tumor markers in breast cancer [6, 7] 
Marker
Assess in 
adjuvant 
setting
Assess in 
metastatic 
setting
Prognostic 
factor
Predictive 
factor
Use for monitoring only
NED Met
Tissue-based ER Yes Yes Weak Stronga N/A N/A
PgR Yes Yes Weak Stronga N/A N/A
Her-2/neu Yes Yes Weak Strongb N/A N/A
Circulating CA 15-3 No Yes No No No Yes
CA 27.29 No Yes No No No Yes
CEA No Yes No No No Yes
Her-2 ECD No No No No No No
aFor benefit from endocrine treatment.
bFor benefit from trastuzumab therapy.
Abbreviations: CA, cancer antigen; CEA, carcinoembryonic antigen; ECD, circulating extracellular domain; ER, estrogen 
receptor; NED, no evidence of disease; Met: metastatic; N/A: not applicable; PgR, progesterone receptor. 
Table 3. Clinical uses of tumor markers
Determine risk of developing disease
Screening for disease
Establish diagnosis
Differentiate benign versus malignant disease
Determine type of malignancy
Determine prognosis
For primary disease, predict relapse
For metastatic disease, predict progression
Predict survival
Predict response to therapy 
Hormone therapy
Chemotherapy
Novel therapies (e.g., trastuzumab) 
Monitor disease
For primary disease, predict relapse
For metastatic disease, follow detectable disease
Adapted from Stearns V, Yamauchi H, Hayes DF. Circulating 
tumor markers in breast cancer: accepted utilities and novel 
prospects. Breast Cancer Res Treat 1998;52:239–259, with 
kind permission of Springer Science and Business Media.
Table 2. Requirements essential for acceptance of a tumor 
marker
Determine utility of marker (Table 3)
Evaluate magnitude of effect (none, weak, moderate, strong)
Analyze reliability of marker
Technical issues (assay)
Analytical issues (cutoff points, test/validation sets,   
 multivariate analysis)
Trial design issues (appropriate patient population)
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we have arbitrarily designated it as a “strong” prognostic 
factor, using it as the gold standard to set the criteria for con-
sideration of other, putative markers [16]. A strong prognos-
tic factor is depicted by Factor 1 in Figure 1A. Alternatively, 
untreated patients with ER-positive breast cancer have only 
slightly better outcomes than those with ER-negative dis-
ease, and therefore we designated ER status as a weak prog-
nostic factor, as portrayed by Factor 2 in Figure 1A [17, 18]. 
In a previous publication, we have suggested hazard ratios 
of <1.5, 1.5–2, and >2, to distinguish weak, moderate, and 
strong prognostic factors, respectively, for breast cancer 
[16]. Such arbitrary designations would need to be estab-
lished for other uses, as appropriate.
Predictive factors can also be classified as weak (Factor 
1), moderate, or strong (Factor 2), depending on their ability 
to predict response to, and therefore benefit from, a given 
therapy, as illustrated in Figure 1B. One measure to permit 
comparison of the relative strengths has been designated 
the “relative predictive value” (RPV), the ratio of the likeli-
hood that a factor-positive patient will respond to treatment 
to the likelihood that a factor-negative patient will respond 
to treatment. As with prognostic factors, we have proposed 
arbitrary classes of prediction factors for breast cancer 
therapies based on what has been accepted by consensus, 
in this case ER [19]. Adjuvant tamoxifen therapy has been 
shown to decrease recurrence rates for ER-positive patients 
by 40%–50%, whereas ER-negative patients obtain mini-
mal, if any, benefit from hormonal therapy [20]. Therefore, 
the RPV is >8. Similarly, the majority of patients with ER-
positive MBC have a clinical response to hormonal therapy, 
whereas patients with ER-negative disease do not respond 
[21, 22]. ER status is therefore a strong predictive factor for 
response to hormonal therapy. In this framework, we have 
arbitrarily proposed that, in breast cancer, weak, moderate, 
and strong predictive factors correspond to RPVs of 1–2, 
2–4, and >4, respectively [15].  It is important to understand 
Figure 1. Schematic representation of prognostic and predictive factors. (A): Pure prognostic factor. (B): Pure predictive fac-
tor. (C): Mixed factor associated with weakly favorable prognosis and strong response to specific therapy.  (D): Mixed factor 
associated with unfavorable prognosis and strong response to specific therapy. Modified from Hayes DF, Trock B, Harris AL. 
Assessing the clinical impact of prognostic factors: when is “statistically significant” clinically useful? Breast Cancer Res Treat 
1998;52:305–319, with kind permission of Springer Science and Business Media.
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the clinical implications of the relative strength of a prog-
nostic and/or predictive factor when integrating this infor-
mation into routine practice, and to determine if the data 
support its use in a specific clinical situation.
How Reliable Is the Tumor Marker 
(Precision and Accuracy)?
The preceding discussion illustrates the importance of esti-
mating the magnitude of the relative tumor marker effect 
for a selected use. However, the marker is only useful if the 
estimate of its magnitude is reliable and reproducible. In this 
regard, many investigators conclude that their marker of 
interest has clinical utility if in their study the difference in 
outcomes between marker “positive” and marker “negative” 
patients is less than conventional measures of statistical sig-
nificant (p < .05). This conclusion may be mistaken. Statisti-
cal significance only suggests that in the population chosen 
for that study, the differences observed are likely not to be 
a result of chance alone. It does not imply clinical utility, 
nor does a p-value <0.05 document the validity of the tumor 
marker. Although it is important to determine that the dif-
ferences in outcome achieve statistical significance, statisti-
cal significance alone does not determine clinical utility. 
In addition to determining when to use a tumor marker 
and the magnitude of its effect, it is important to ensure that 
the technical aspects of the marker are reliable and repro-
ducible and that the study design and conduct are appropri-
ate to test the marker for a clinical use of interest. Several 
problems with tumor marker studies, including technical, 
analytical, and trial design issues, have limited the intro-
duction of new prognostic and predictive factors into rou-
tine clinical practice [11].
What Technical Factors Influence Measurement 
of Markers?
From a technical standpoint, difficulties arise because of 
poor sensitivity and/or specificity of the assay for the ana-
lyte, poorly reproducible assays, and differences between 
assays that use different reagents for measurement of the 
same marker [11]. Even for the two most commonly used 
and accepted tumor markers, ER expression and Her-2/neu 
overexpression, standard methodologies have not yet been 
established [4, 5]. Two primary technical considerations 
are critical when measuring a tumor marker. The first is 
which type of assay should be used. The second is the repro-
ducibility of the chosen assay, from both a technical and an 
analytical perspective. 
For example, Her-2/neu status can be determined by 
measures of protein expression (by immunohistochemis-
try [IHC], Western blotting, or enzyme-linked immuno-
sorbent assay), measures of RNA expression (by Northern 
blotting or reverse transcriptase-polymerase chain reaction 
[RT-PCR]), and/or measures of DNA amplification (by 
fluorescence or chromogenic in situ hybridization [FISH 
and CISH, respectively]). Furthermore, even within these 
categories, different reagents (e.g., different antibodies in 
IHC assays) are used in different tests. The results are not 
interchangeable, either within or between classes of assays, 
and therefore researchers must decide which methodology 
they will employ. Once that decision is made, researchers 
must then decide how to perform the assay. For example, 
when assessing Her-2/neu overexpression by IHC, tech-
nical issues such as antibody concentration and antigen 
retrieval methods may cause unacceptably high false-posi-
tive or false-negative rates. 
In one study, IHC and FISH resulted in only a 65% 
agreement for Her-2/neu status [23]. In a different study, 
results obtained from local laboratories were compared 
with those from a central laboratory for two Her-2/neu 
assays, the HercepTest™ IHC assay (Dako North America, 
Inc., Carpinteria, CA) and the FISH assay, with 79% con-
cordance for HercepTest™ and 85% concordance for FISH 
[24]. Therefore, for the same test at multiple laboratories, 
and for different tests for the same marker, there is a signifi-
cant degree of discordance for two commonly used tests for 
the evaluation of Her-2/neu status.
The stakes are high. Recently reported data suggest 
that adjuvant trastuzumab decreases recurrence rates by 
50%. However, up to 5% of patients who receive trastu-
zumab develop cardiac dysfunction, and the cost of 1 year 
of therapy may exceed $100,000. Therefore, it is essential 
that Her-2/neu, the target for trastuzumab, be assayed accu-
rately and precisely for every tissue sample. Expert panels 
are now being convened to establish guidelines for the con-
duct and interpretation of common tumor marker assays, 
including ER and Her-2/neu. These guidelines should lead 
to standardization of the assays, which should allow for 
more reliable results both for routine clinical practice and 
for use of these assays in clinical trials.
What Analytical Issues Are Important 
to Consider?
Assay Interpretation
Determination of assay results can also vary, even for a single 
type of assay. For example, with visual assays such as IHC 
for ER and Her-2/neu, intra- and interobserver variability 
leads to differences in interpretation [25, 26]. Some attempts 
have been made to standardize interpretation, such as devel-
opment of the so-called “Allred score” for semiquantitation 
of ER expression [27], but these have not been universally 
adopted. Automated and semiautomated systems appear to 
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be highly accurate and are likely to be more reproducible. 
Examples of automated systems include the ChromaVision 
ACIS® system (ChromaVision Medical Systems, Inc., San 
Juan Capistrano, CA) for ER expression measurement, the 
CellSearch™ assay (Veridex, LLC, Warren, NJ) for detec-
tion of circulating tumor cells [28], and the Oncotype DX™ 
assay (Genomic Health, Inc., Redwood City, CA), a new 
prognostic tool for patients with hormone receptor (HR)-
positive, lymph node-negative breast cancer [29].
Cutoff Point Determination
Regardless of the assay, one has to select some value or level 
that distinguishes positive from negative results. However, 
there is no consensus regarding correct methods to establish 
cutoff points, and different studies of the same prognostic or 
predictive factor can have widely varying “optimal” cutoff 
points [30]. 
Cutoff points may be defined using either arbitrary or 
data-derived methods (Table 4). One approach is to con-
sider any value greater than two standard deviations above 
the mean for normal subjects to be positive. Cutoff points 
can also represent arbitrary values within affected patients; 
for example, one might decide that 10%, 50%, or 90% of 
affected patients will be classified as “positive.”  Others 
have defined cutoff points based on technical factors, such 
as the limit of detection of the assay [21]. Finally, the cutoff 
point for a new assay can be defined by comparing it with an 
older assay [27]. 
Deriving cutoff points based on patient outcome data 
may provide more accurate values. For example, the cutoff 
point for ER expression was first defined by limits of the 
assay and later by determining the optimal level that dis-
tinguished those patients who respond to hormonal therapy 
from those who do not. In another example, the cutoff point 
for the CellSearch™ assay for circulating tumor cells was 
initially determined based on differences in time to pro-
gression of a test set of patients with metastatic disease, and 
this cutoff was then validated with an independent but simi-
lar patient cohort from the same study [31]. Another com-
mon method to generate a data-derived cutoff point is to 
construct a receiver operating characteristic curve, which 
demonstrates the tradeoff between the sensitivity and spec-
ificity of an assay at different cutoff points.
Recently, a novel data-derived method to select cutoff 
points, designated subpopulation treatment effect pattern 
plot (STEPP) analysis, has been proposed [32].  STEPP 
analysis evaluates outcomes to specific treatments in sub-
populations of patients within randomized clinical trials or 
meta-analyses [32]. For example, it has been proposed that 
recurrence rates after treatment with chemotherapy should 
be evaluated in the context of the endocrine responsiveness 
of tumors, since HR-positive and -negative tumors appear 
to behave differently. Rather than arbitrarily defining cutoff 
points for ER positive and negative, the authors performed 
a STEPP analysis of data from a previously conducted ran-
domized clinical trial and were able to demonstrate a ben-
efit from chemotherapy only in the subset of patients with 
very low ER values. 
Cutoff Point Validation
Regardless of whether cutoff points are chosen arbitrarily 
or are data-derived, the selected cutoffs require subsequent 
validation. The initial evaluation should be performed using 
a “test set” of patients. In the second part of the study, the 
utility of the cutoff point should then be confirmed using a 
separate “validation set” composed of a similar, but com-
pletely independent, patient population. 
For example, the Oncotype DX™ assay is based on the 
principle of evaluating expression of multiple candidate 
genes using quantitative RT-PCR [29]. The investigators 
initially screened more than 200 candidate genes with 
the aim of developing a test that would predict the likeli-
hood of recurrence of cancer in patients with HR-positive, 
lymph node-negative breast cancer. Breast cancer tissues 
from 447 patients with HR-positive, lymph node-negative 
tumors were used retrospectively to generate an algorithm 
using 16 of these genes that permitted division of patients 
into subgroups with very low, intermediate, or very high 
risk for recurrence. Patients are assigned to these groups 
based on a “recurrence score” derived from the algo-
rithm. The majority of the test samples were obtained 
from patients treated with tamoxifen alone in the National 
Surgical Adjuvant Breast and Bowel Project (NSABP) 
B-20 trial [33], and the data-derived algorithm was then 
validated using a separate retrospective cohort of patients 
from the NSABP B-14 trial [34], who had similar clini-
cal characteristics and were also treated with tamoxifen 
alone. If the cohorts had different clinical characteristics 
or had been treated differently, the validation would not 
Table 4.  Methods used for selection of cutoff points
Arbitrary
Based on limit of detection of the assay
Defined as two standard deviations above the mean of 
normal patients
Defined based on mean value in affected versus normal 
patients
“Appropriate” percentage of positive cells 
Data-derived
Plot p-value versus outcome
Plot magnitude of effect of marker versus outcome
Receiver operating characteristic curve
Subpopulation treatment effect pattern plot analysis
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have been legitimate. Validation of the results in a sepa-
rate patient population strongly suggests that the test is 
reliable and that the results are likely to be meaningful in a 
larger population, as long as the patients tested are similar 
to the cohorts included in the original studies.  
Statistical Analysis
Of course, statistical analysis is necessary to determine that 
the observations are not a result of chance alone. However, 
once a tumor marker has been identified and validated, it is 
important to determine the relative value of the marker in 
the context of previously identified prognostic and/or pre-
dictive factors, such as lymph node status and tumor size, 
using some type of a multivariate analysis. If such an evalu-
ation is not performed, clinicians will be unable to deter-
mine the usefulness of incorporating the new marker into 
routine clinical practice.
Trial Design and Frameworks for 
Generating, Reporting, and Evaluating 
Tumor Marker Results
One of the key steps in identifying and confirming the 
benefit of a new tumor marker is appropriate study design. 
The Tumor Marker Utility Grading System (TMUGS) 
was initially developed by members of the ASCO panel 
to provide a framework within which the utility of tumor 
markers can be graded based on published information 
[11]. Markers are assigned a grade based on the level of 
evidence (LOE) available. These LOE reflect the relative 
quality of the studies used to generate an estimate of the 
effect of the marker (Table 5). LOE I and II studies are 
the most beneficial for evaluating the utility of a tumor 
marker. According to the TMUGS framework, the ideal 
clinical trial is a properly powered, prospective, random-
ized trial designed specifically to evaluate the clinical 
utility of a tumor marker in question for a specific and pre-
designated use. In such a study, diagnostic and/or thera-
peutic decisions for the study arm are based on the tumor 
marker in question, whereas the decisions for the control 
arm are made independently [11]. 
Systematic overviews and/or pooled analyses of well-
conducted LOE II studies are equivalent to LOE I stud-
ies, especially if the correlative studies address a specific 
use but are underpowered in a single study. It has been 
estimated that a clinical trial that has been appropriately 
powered to determine a clinical end point, such as progres-
sion-free survival, is underpowered for analysis of tumor 
marker-designated subgroups by one fourth, even if tissue 
from 100% of enrollees is available. Moreover, interpreta-
tion still requires judgment regarding the clinical impor-
tance of the finding. 
For example, from the prospective randomized clinical 
trials of adjuvant trastuzumab versus placebo, we anticipate 
combined analyses of the multiple underpowered LOE II 
studies evaluating novel markers for benefit from this drug. 
These pooled results should help focus trastuzumab therapy 
in the subgroups of Her-2/neu-positive patients most likely 
to benefit. The combined analyses of small LOE III studies 
that contain patients with variable clinical characteristics 
and treatments, however, are more likely useful to generate 
new hypotheses than to provide clinically useful and vali-
dated results. 
For all studies, whether prospective or retrospective, it 
is important to identify the appropriate patient population 
to be investigated. All patients should have a similar profile 
based on known prognostic factors. Importantly, the effects 
Table 5. Levels of evidence for determining utility of tumor marker
Level Type of evidence
I Evidence from a single, high-powered, prospective controlled study that is specifically designed to test marker, or 
evidence from well-done meta-analysis and/or overview of level I studies. Ideally, the study is a prospective, 
randomized controlled trial in which diagnostic and/or therapeutic clinical decisions in one arm are determined at least 
in part on the basis of marker results, and diagnostic and/or therapeutic clinical decisions in the control arm are made 
independently of marker results, or 
Evidence from overview of level of evidence II studies addressing specific use.
II Evidence from study in which marker data are determined in relationship to prospective therapeutic trial that is 
performed to test therapeutic hypothesis but not specifically designed to test marker utility. Specimen collection for 
marker study and statistical analysis are prospectively determined in protocol as secondary objectives.
III Evidence from large but retrospective studies from which variable numbers of samples are available or selected. 
Statistical analysis for tumor marker was not dictated prospectively at time of therapeutic trial design. 
IV Evidence from small retrospective studies that do not have prospectively dictated therapy, follow-up, specimen 
selection, or statistical analysis.
V Evidence from small pilot studies designed to determine or estimate distribution of marker levels in sample populations. 
Reprinted from Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: a framework to evaluate clinical utility 
of tumor markers. J Natl Cancer Inst 1996;88(20):1456–1466, permission of Oxford University Press.
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of systemic treatment are critical and must be considered. 
If the study is addressing the prognostic value of a marker, 
all patients should have been treated uniformly and without 
whatever treatment might be considered if the patients have 
a “poor prognosis.” If the question is addressing the utility 
of adding any treatment, all patients should be untreated. 
If the question is whether more treatment should be given, 
then all patients should have received the same treatment. 
If the study is addressing predictive factors, a control 
group that has been treated identically to the study group, 
with the exception that they did not receive the treatment 
in question, is essential. Although the control group might 
be from a selected historical control, predictive factors are 
ideally studied in the context of prospective, randomized, 
controlled trials comparing the patients who received the 
treatment in question with those who did not receive that 
treatment. 
Tumor marker studies should be carefully designed, 
using the above criteria, to obtain clinically useful infor-
mation. Researchers frequently have practical difficulties 
designing such studies, however, because of the need for sig-
nificant numbers of patients with particular clinical char-
acteristics in order to address a specific clinical question. 
As discussed above, this can sometimes be overcome by 
pooling the results of several well-done but underpowered 
studies. Another significant drawback is obtaining fund-
ing for tumor marker studies, as pharmaceutical companies 
and third-party payers derive relatively smaller financial 
benefit from the results compared to the enormous payoffs 
for a “blockbuster” therapeutic agent. Regardless, given the 
consequences, one has to question why it is acceptable for 
tumor marker studies to be performed with less scientific 
rigor than studies of new pharmaceutical agents.
Reporting of tumor marker studies has also been his-
torically haphazard. Recently, in order to standardize 
reporting of tumor marker study results, the National Can-
cer Institute-European Organization for Research and 
Treatment of Cancer (NCI-EORTC) Working Group on 
Cancer Diagnostics developed REporting recommenda-
tions for tumor MARKer prognostic studies (REMARK) 
[35]. The guidelines outline items that should be 
addressed by researchers when reporting the results of 
tumor marker studies, including prospectively defining 
the question the study is trying to address, identifying the 
appropriate patient population and controls, determining 
the end point, and identifying potential confounding fac-
tors. Explicit recommendations are given regarding which 
information must be contained in publications of tumor 
marker studies, including patient and treatment infor-
mation, specimen characteristics, assay methods, study 
design, and statistical analysis methods. 
Real-World Clinical Examples
In the preceding sections we identified the essential ele-
ments for establishing the usefulness, strength, and reli-
ability of tumor markers. Let us now discuss the data sup-
porting two currently used tumor markers, Her-2/neu and 
Oncotype DX™.
Her-2/neu 
The first report of Her-2/neu as a prognostic factor in breast 
cancer was published in 1987 [36]. Since then, more than 
200 papers addressing this topic have been published, with 
widely mixed and disparate results [37]. Different authors 
have concluded that Her-2/neu is associated with poor out-
comes, no difference in outcome, or even favorable out-
comes. Indeed, a great deal of this confusion could have 
been avoided if the investigators would have addressed the 
components described above: (a) What is the intended use, 
(b) What is the magnitude of difference between positive 
and negative for that use, and (c) How reliable is the esti-
mate of the magnitude? 
The potential uses for Her-2/neu are for prognosis and 
prediction, as outlined in Table 6. Issues related to the reli-
ability of the assays have been described in detail above. 
Overall, studies support that Her-2/neu overexpression is 
a poor prognostic factor, although its magnitude appears 
weak. For example, in Adjuvant! Online it has only a rela-
tive predictive value of 1.5 [38]. Its role as a prognostic fac-
tor thus remains unclear. 
More data exist to support the role of Her-2/neu status for 
prediction of response to standard therapies and trastuzumab. 
For selective estrogen receptor modulators (SERMs), such 
as tamoxifen, preclinical and clinical studies suggest that 
Her-2/neu positivity confers a relative resistance, with mod-
erate magnitude, although the data are LOE III at best [39]. 
Data for aromatase inhibitors (AIs) are mixed, although in 
one pilot study of neoadjuvant endocrine therapy, Her-2/neu 
overexpression correlated with lower response to tamoxifen 
than to AIs [39]. At present, Her-2/neu status is not used to 
determine which endocrine therapy to use, because of the 
poor level of available evidence and conflicting data. Con-
firmation of these results may lead to preferential use of AIs 
in patients with Her-2/neu-positive disease.
Patients with tumors that overexpress Her-2/neu appear 
to have relative resistance to some chemotherapy regimens, 
such as cyclophosphamide, methotrexate, and 5-fluoroura-
cil (CMF), but not to others, such as anthracycline-contain-
ing regimens [37, 40, 41]. Her-2/neu status is not generally 
a consideration when choosing a chemotherapy regimen, 
however, because, as is the case with endocrine therapy, the 
level of available evidence does not support using Her-2/neu 
status to predict response to chemotherapy.
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In contrast, Her-2/neu status appears to be strongly pre-
dictive of response to trastuzumab. A patient with a tumor 
that overexpresses Her-2/neu is usually treated with trastu-
zumab in either the adjuvant or metastatic settings [8, 9, 42, 
43] because the benefits outweigh the risks in the majority of 
cases. A patient with a tumor that fails to overexpress Her-
2/neu appears not to respond to treatment with trastuzumab 
[10, 44] and therefore would not be treated with trastuzumab 
to avoid both unnecessary toxicity and cost. Thus, use of 
Her-2/neu to select trastuzumab is recommended based on 
“use” and “magnitude.” However, as discussed above, there 
are substantial apparent difficulties with the technical reli-
ability of all available assays for the marker. Nonetheless, 
despite the shortcomings of Her-2/neu studies outlined 
above, at present there is sufficient LOE II evidence to sup-
port the routine clinical use of Her-2/neu overexpression for 
selection of trastuzumab therapy, as indicated in the most 
recent ASCO tumor marker guidelines [4]. 
Multigene Expression: Oncotype DX™
A more recent example of development of a new tumor 
marker is provided by the case of Oncotype DX™. The 
investigators specifically developed the test to determine 
prognosis in ER-positive, lymph node-negative patients 
who were treated with tamoxifen [29]. The available results 
suggest that, in this group of patients, Oncotype DX™ is 
a strong prognostic factor because the ratio of the hazard 
ratios of the high and low recurrence score cohorts is >2 
in both the test and validation cohorts [29]. The Oncotype 
DX™ test is also reliable because it fulfills the criteria out-
lined above for technical, analytical, and trial design issues 
(Table 2). The assay is reproducible and was validated in 
independent test and validation cohorts of patients, as 
described above.
Oncotype DX™ has also been evaluated as a predic-
tive factor, although less rigorously. In the NSABP B-14 
trial, the patient cohorts were treated with tamoxifen ver-
sus observation, and comparison of the cohorts suggested 
that the Oncotype DX™ assay is predictive for tamoxifen 
[45]. Similarly, analysis of NSABP B-20, in which patients 
were randomized to CMF and tamoxifen versus tamoxi-
fen alone, permitted the investigators to determine that the 
assay is predictive for response to chemotherapy [45].
Are the available data sufficient to conclude that Onco-
type DX™ has been validated to the extent that patient 
treatment decisions should be based on the results? Perhaps, 
but because these studies were all proposed using available 
samples from trials performed many years ago and repre-
sented only subsets of the overall population entered into 
the trials, concerns have been raised about wholesale clini-
cal adoption of this assay. In that regard, the North Ameri-
can Breast Cancer Intergroup is developing the TailorRx 
clinical trial to further validate and extend the Oncotype 
DX™ results. The trial design assumes that the assay is 
prognostic, and will confirm the ability of the assay to pre-
dict response to chemotherapy.
In the TailorRX trial, tumors of patients with ER-posi-
tive and lymph node-negative breast cancer will be tested 
using the Oncotype DX™ assay. Patients with low recur-
rence scores, who have good prognoses without chemo-
therapy, will receive hormonal therapy alone. At the other 
end of the spectrum, patients with high recurrence scores 
will receive chemotherapy in addition to hormonal ther-
apy. Those patients whose scores fall in the intermediate 
range will all receive hormonal therapy and be randomly 
assigned to chemotherapy or not. This trial design will 
permit validation of the Oncotype DX™ results in a simi-
lar patient population in a large prospective clinical trial, 
Table 6. Theoretical uses for tissue-based Her-2/neu assessment
Use Effecta Magnitude LOE
Prognosis Negative Moderate III
Prediction
 Hormone therapy
  SERM Negative Weak-moderate III
  AI Neutral N/A III
 Chemotherapy
  Nonanthracycline Negative Weak-moderate III
  Anthracycline Positive or Neutral Moderate or N/A III
 Trastuzumab Positive Strong II
aNegative indicates worse outcome if Her-2/neu-positive; positive indicates better outcome if Her-2/neu-positive; neutral  
indicates outcome same regardless of Her-2/neu result.
Abbreviations: AI, aromatase inhibitor; LOE, level of evidence; N/A, not applicable; SERM, selective estrogen receptor modulator.
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and will allow for generation of new data on which to base 
treatment recommendations for patients whose recurrence 
scores are intermediate.
Given the substantial technical, analytical, and trial 
design problems with previously performed tumor marker 
studies, it is imperative to address these issues. It is espe-
cially important to standardize the assays for commonly 
used tumor markers. Otherwise, patients with false-posi-
tive test results for predictive factors will receive treatments 
that are not beneficial but which may cause significant 
toxicity, and those with false-negative results will not be 
offered potentially life-saving therapies. In addition, a bet-
ter understanding of the potential pitfalls in tumor marker 
study design will allow for the development of new, poten-
tially more useful assays. 
Conclusions
Tumor markers, when well defined, can play a significant 
role in prediction and prognosis for breast cancer patients. 
Because of the abundance of poorly designed tumor marker 
studies to date, however, very few markers have been 
accepted for routine use by groups such as ASCO. When 
designing studies to establish a new tumor marker, or new 
use for an old marker, it is important to address the utility, 
magnitude, and reliability of the marker (Table 2). 
Frameworks such as TMUGS can be useful when 
designing and conducting these studies to ensure that 
appropriate components are included, thereby leading to 
the establishment of new tumor markers for routine clinical 
use [11]. By progressively generating and refining a hypoth-
esis, based on data derived from increasingly well-devel-
oped studies, tumor markers with clinical utility can be 
identified (Fig. 2). In addition, the new REMARK guide-
lines should promote better design and conduct of stud-
ies specifically focused on tumor marker validation [35]. 
Implementation of these recommendations when designing 
tumor marker studies will result in the generation and pub-
lication of appropriate and complete clinical data, leading 
to the adoption of new, well-validated tumor markers for 
routine clinical use.
Figure 2. Tumor marker development flow chart. LOE, level of evidence; MVA, multivariate analysis.
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